The Heart and Estrogen/Progestin Replacement Study (HERS) in perspective - Results not very surprising

Acta Obstetricia et Gynecologica Scandinavica

Volumn 79, Issue 12, 2000, Pages 1037-1041

  Naessen, T ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Cardiovascular disease; Menopausal estrogen therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

AGED; ATHEROSCLEROSIS; CORONARY RISK; DOSE RESPONSE; ESTROGEN THERAPY; FEMALE; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MENOPAUSE; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE CONGENERS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS;

EID: 0033662398     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0412.2000.0790121037.x     Document Type: Note

References (50)

1. A prospective study of postmenopausal estrogen therapy and coronary heart disease
2. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
3. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study
4. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement
5. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
6. Hormones and heart disease in women: Heart and estrogen/progestin replacement study in perspective
7. Prior to use of estrogen replacement therapy, are users healthier than nonusers?
8. The relationship of treatment adherence to the risk of death after myocardial infarction in women
9. Cardioprotective effect of hormone replacement therapy. Is not due to selection bias
10. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women
11. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women
12. Estrogen replacement therapy and prognosis after first myocardial infarction
13. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
14. Hormone replacement therapy and heart disease prevention: Experimentation trumps observation
15. Lifetime risk of developing coronary heart disease
16. Menopause and risk factors for coronary heart disease
17. Postmenopausal changes of lipid and glucose metabolism: A review of their main aspects
18. Influence of menopause on serum lipids and lipoproteins
19. A prospective one-year study of estrogen and progestin in postmenopausal women: Effects on clinical symptoms and lipoprotein lipids
20. Effects of long-term transdermal administration of estradiol on serum lipids
21. Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: The effects on lipoprotein metabolism in postmenopausal women
22. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial
23. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations
24. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
25. Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women
26. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
27. Hormone therapy to prevent disease and prolong life in postmenopausal women
28. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women
29. Cardiovascular implications of estrogen replacement therapy
30. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators
31. Protective effect of 17 beta-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells
32. Carotid artery wall thickness in women treated with hormone replacement therapy
33. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone
34. Hormone replacement therapy and the cardiovascular system. Nonlipid effects
35. 17 beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine
36. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
37. Risk of venous thromboembolism in users of hormone replacement therapy
38. Hormone replacement therapy with estradiol and risk of venous thromboembolism - A population-based case-control study
39. Initial findings leading to modifications of its research protocol
40. Findings leading to discontinuation of the 25-mg day estrogen group
41. A case-control study of myocardial infarction in relation to use of estrogen supplements
42. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women
43. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
44. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy
45. Age-related changes in human oestrogen receptor alpha function and levels in osteoblasts
46. Sex steroid receptors in human myometrium and fibroids: Changes during the menstrual cycle and gonadotropin-releasing hormone treatment
47. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol
48. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
49. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)